PDB54 COMPARISON OF TREATMENT COSTS BETWEEN BASAL-SUPPORTED ORAL THERAPY (BOT) WITH INSULIN GLARGINE (GLA) AND BOT WITH INSULIN DETEMIR (DET) IN PATIENTS WITH TYPE 2 DIABETES (T2D)- ECONOMIC EVALUATION BASED ON THE RESULTS OF THE INSULIN GL ...
Abstract
Authors
PK SchAdlich KC Koltermann FW Dippel EG Hagenmeyer B HAussler